6.56 -0.43 (-6.15%) | 04-25 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 10.22 | 1-year : | 11.93 |
Resists | First : | 8.75 | Second : | 10.22 |
Pivot price | 5.73 | |||
Supports | First : | 5.1 | Second : | 2.84 |
MAs | MA(5) : | 6.79 | MA(20) : | 5.12 |
MA(100) : | 3.69 | MA(250) : | 3.56 | |
MACD | MACD : | 0.9 | Signal : | 0.7 |
%K %D | K(14,3) : | 63.1 | D(3) : | 64.6 |
RSI | RSI(14): 62.3 | |||
52-week | High : | 8.75 | Low : | 1.82 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RANI ] has closed below upper band by 34.6%. Bollinger Bands are 307.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 7.24 - 7.27 | 7.27 - 7.31 |
Low: | 6.16 - 6.2 | 6.2 - 6.23 |
Close: | 6.49 - 6.56 | 6.56 - 6.62 |
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Thu, 25 Apr 2024
Rani Therapeutics to Present at Cantor Fitzgerald Virtual Global Healthcare Conference - The Globe and Mail
Wed, 24 Apr 2024
Despite Rani Therapeutics Holdings' Pullback, Insiders Still Gained US$419k - Simply Wall St
Thu, 18 Apr 2024
Rani Therapeutics (NASDAQ:RANI) Trading Up 14.3% - MarketBeat
Wed, 20 Mar 2024
Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load? - Simply Wall St
Wed, 20 Mar 2024
Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript - Seeking Alpha
Wed, 20 Mar 2024
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 26 (M) |
Shares Float | 13 (M) |
Held by Insiders | 47.9 (%) |
Held by Institutions | 13.2 (%) |
Shares Short | 1,920 (K) |
Shares Short P.Month | 1,710 (K) |
EPS | -1.34 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.49 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -49.8 % |
Return on Equity (ttm) | -136.6 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -2.49 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -51 (M) |
Levered Free Cash Flow | -27 (M) |
PE Ratio | -4.94 |
PEG Ratio | 0.7 |
Price to Book value | 13.38 |
Price to Sales | 0 |
Price to Cash Flow | -3.37 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |